Abstract
There is currently considerable debate in many countries over the effects of public policy — in particular, governmental regulation — on the development of innovative pharmaceuticals. Regulators must balance patients' access to therapies with ensuring the safety of drugs. The consequences of poor decisions can be dire: if access is promoted at the expense of safety, a dangerous product can cause incalculable harm; conversely, if safety is over-emphasized at the expense of access, patients can suffer from the absence of life-saving and life-enhancing medications. Using the United States as an example, we discuss the influence of governmental bodies such as the US Food and Drug Administration (FDA), as well as recent legislative initiatives, on pharmaceutical innovation. We argue for a balanced approach to governmental interventions.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Risk management of biosimilars in oncology: each medicine is a work in progress
Targeted Oncology Open Access 25 January 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cutler, D., McClellan, M. & Newhouse, J. The Costs and Benefits of Intensive Treatment for Cardiovascular Disease (The American Enterprise Institute for Public Policy Research/Brookings Institution, Washington DC, December 1997).
Frank, R. G., Berndt, E. & Busch, S. H. Price Indexes for the Treatment of Depression (The American Enterprise Institute for Public Policy Research/Brookings Institution, Washington DC, December 1997).
Fagan, S. C. et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 50 883–889 (1998).
Legg, R. F. et al. Cost benefit of sumatriptan to an employer. J. Occup. Environ. Med. 39, 652–657 (1997).
Lichtenberg, F. R. The effect of drug vintage on survival: micro evidence from Puerto Rico's medicaid program. National Bureau of Economic Research Working Paper No.10884. National Bureau of Economic Research web site [online], (November 2004).
Vernon, J. A., Santerre, R. E. & Giaccotto, C. Medical progress report. Are drug price controls good for your health? Manhattan Institute for Policy Research web site [online], (December 2004).
Miller, H. I. To America's Health: A Proposal to Reform the Food & Drug Administration (Hoover Institution Press, Stanford, California, 2000).
Miller, H. I. A proposal for FDA reform. Nature Rev. Drug Discov. 1, 642–648 (2002).
Genentech Press Release. Genentech receives complete response letter from FDA for avastin in metastatic breast cancer. Genentech Press Releases homepage [online], (11 September 2006).
Pollack, A. New sense of caution at F.D.A. New York Times [online], (29 September 2006).
Brown, C. A. & Johnson, T. C. Conditioning FDA Approval on Agreement Not to Advertise Violates Law and Constitution Vol. 20 (Washington Legal Foundation Legal Backgrounder, Washington DC, 1 September 2006).
US Department of Health and Human Services Food and Drug Administration. Guidance for industry development and use of risk minimization action plans. FDA web site [online], (March 2005).
Committee on the Assessment of the US Drug Safety System. The future of drug safety: promoting and protecting the health of the public. Institute of Medicine of the National Academies web site [online], (2007).
Drug Safety Oversight Board. Center for Drug Evaluation and Research manual of policies and procedures [online], (2 March 2007).
US Department of Health and Human Services. Drug safety information — FDA's communication to the public [online], (March 2007).
Speech before the National Press Club on 'Dismantling Barriers to Better Medical Information'. Remarks by Scott Gottlieb, MD, Deputy Commissioner for Medical and Scientific Affairs [online], (28 September 2005).
Simon, V. Wanted: women in clinical trials. Science 308, 1517 (2005).
Philipson, T. J., Berndt, E. R., Gottschalk, A. H. B. & Strobeck, M. W. Assessing the safety and efficacy of the FDA: the case of the prescription drug user fee acts. National Bureau of Economic Research Working Paper No. 11724. Social Science Research Network web site [online], (October 2005).
Walker, P. Testimony of Pamela Walker, Mitretek Systems, before the Committee on Labor and Human Resources of the US Senate. (21 February 1996).
European Commission Enterprise and Industry. Notified bodies. Single Market — Regulatory Policy web page [online], (18 October 2006).
Friedman, M. & Friedman, R. D. in Thinking About America: the United States in the 1990s (eds Anderson, A. & Bark, D. L.) 467 (Hoover Institution Press, Stanford, California, 1988).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
DATABASES
OMIM
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Miller, H., Henderson, D. Governmental influences on drug development: striking a better balance. Nat Rev Drug Discov 6, 532–539 (2007). https://doi.org/10.1038/nrd2323
Issue Date:
DOI: https://doi.org/10.1038/nrd2323
This article is cited by
-
Risk management of biosimilars in oncology: each medicine is a work in progress
Targeted Oncology (2012)
